With NIO's better-than-expected second-quarter results, let's examine the company's fundamentals to determine if now is the right time to buy its...

With NIO's better-than-expected second-quarter results, let's examine the company's fundamentals to determine if now is the right time to buy its...

STX's growth prospects look promising amid increasing mass capacity demand and improving margin performance.

GCT appears less attractive as the company's ongoing operational challenges and worsening earnings estimates present uncertain prospects.

Teva's reasonable valuation, an improving pipeline and the prospect of growth in sales and profits are good enough reasons for those who own the stock...

Solid global presence, a compelling product portfolio, increased electronic trading and a focus on over-the-counter clearing services poise CME for...

AMGN's reasonable valuation, an interesting pipeline and continued top-line growth are good enough reasons to stay invested for now.

NVIDIA's shares lately took a beating as regulators launched a probe into the company's contracts. Is it the right time to sell the NVDA stock, or...

NVIDIA's shares lately took a beating as regulators launched a probe into the company's contracts. Is it the right time to sell the NVDA stock, or...

Despite SNPS stock's price drop, the company's AI-driven growth potential and strategic acquisitions make a compelling case for holding it for now.